184 related articles for article (PubMed ID: 31155562)
1. Design, Synthesis and Biological Evaluation of Novel Nonsteroidal Progesterone Receptor Antagonists Based on Phenylamino-1,3,5-triazine Scaffold.
Kaitoh K; Nakatsu A; Mori S; Kagechika H; Hashimoto Y; Fujii S
Chem Pharm Bull (Tokyo); 2019; 67(6):566-575. PubMed ID: 31155562
[TBL] [Abstract][Full Text] [Related]
2. Development of 1,3-diphenyladamantane derivatives as nonsteroidal progesterone receptor antagonists.
Mori S; Takeuchi Y; Tanatani A; Kagechika H; Fujii S
Bioorg Med Chem; 2015 Feb; 23(4):803-9. PubMed ID: 25593098
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.
Fan YB; Li K; Huang M; Cao Y; Li Y; Jin SY; Liu WB; Wen JC; Liu D; Zhao LX
Bioorg Med Chem Lett; 2016 Feb; 26(4):1224-8. PubMed ID: 26804231
[TBL] [Abstract][Full Text] [Related]
5. Development of p-carborane-based nonsteroidal progesterone receptor antagonists.
Fujii S; Nakano E; Yanagida N; Mori S; Masuno H; Kagechika H
Bioorg Med Chem; 2014 Oct; 22(19):5329-37. PubMed ID: 25151087
[TBL] [Abstract][Full Text] [Related]
6. Rational design and synthesis of 6-aryl-6H-benzo[c]chromenes as non-steroidal progesterone receptor antagonists for use against cancers.
Qin J; Qu S; Zhu K; Cheng Y; Pan G; Jing W; Liu X; Sun X; Liu L
Bioorg Med Chem; 2021 Feb; 32():116003. PubMed ID: 33461148
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of nonsteroidal progesterone receptor antagonists based on C,C'-diphenylcarborane scaffold as a hydrophobic pharmacophore.
Fujii S; Yamada A; Nakano E; Takeuchi Y; Mori S; Masuno H; Kagechika H
Eur J Med Chem; 2014 Sep; 84():264-77. PubMed ID: 25036787
[TBL] [Abstract][Full Text] [Related]
8. Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Zajc I; Filipič M; Solmajer T; Perdih A
Bioorg Med Chem Lett; 2014 Dec; 24(24):5762-5768. PubMed ID: 25453816
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
Zhou X; Lin K; Ma X; Chui WK; Zhou W
Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors.
Oudah KH; Najm MAA; Samir N; Serya RAT; Abouzid KAM
Bioorg Chem; 2019 Nov; 92():103239. PubMed ID: 31513938
[TBL] [Abstract][Full Text] [Related]
11. Development of
Yamada A; Kazui Y; Yoshioka H; Tanatani A; Mori S; Kagechika H; Fujii S
ACS Med Chem Lett; 2016 Dec; 7(12):1028-1033. PubMed ID: 27994732
[TBL] [Abstract][Full Text] [Related]
12. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
[TBL] [Abstract][Full Text] [Related]
13. 1,2,4-Triazine Sulfonamides: Synthesis by Sulfenamide Intermediates, In Vitro Anticancer Screening, Structural Characterization, and Molecular Docking Study.
Branowska D; Karczmarzyk Z; Wolińska E; Wysocki W; Morawiak M; Urbańczyk-Lipkowska Z; Bielawska A; Bielawski K
Molecules; 2020 May; 25(10):. PubMed ID: 32429377
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides.
Kothayer H; Elshanawani AA; Abu Kull ME; El-Sabbagh OI; Shekhar MP; Brancale A; Jones AT; Westwell AD
Bioorg Med Chem Lett; 2013 Dec; 23(24):6886-9. PubMed ID: 24153206
[TBL] [Abstract][Full Text] [Related]
15. Novel Non-steroidal Progesterone Receptor Ligands Based on m-Carborane Containing a Secondary Alcohol: Effect of Chirality on Ligand Activity.
Mori S; Takagaki R; Fujii S; Urushibara K; Tanatani A; Kagechika H
Chem Pharm Bull (Tokyo); 2017; 65(11):1051-1057. PubMed ID: 29093292
[TBL] [Abstract][Full Text] [Related]
16. Development of Boron-Cluster-Based Progesterone Receptor Antagonists Bearing a Pentafluorosulfanyl (SF
Mori S; Tsuemoto N; Kasagawa T; Nakano E; Fujii S; Kagechika H
Chem Pharm Bull (Tokyo); 2019; 67(12):1278-1283. PubMed ID: 31787654
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives.
Khoshneviszadeh M; Ghahremani MH; Foroumadi A; Miri R; Firuzi O; Madadkar-Sobhani A; Edraki N; Parsa M; Shafiee A
Bioorg Med Chem; 2013 Nov; 21(21):6708-17. PubMed ID: 23993677
[TBL] [Abstract][Full Text] [Related]
18. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
20. 6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence.
Sakai H; Hirano T; Mori S; Fujii S; Masuno H; Kinoshita M; Kagechika H; Tanatani A
J Med Chem; 2011 Oct; 54(20):7055-65. PubMed ID: 21916484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
